USPH
U.S. Physical Therapy, Inc. NYSE Listed May 29, 1992$59.01
Mkt Cap $897.2M
52w Low $58.52
1.4% of range
52w High $93.50
50d MA $76.43
200d MA $80.57
P/E (TTM)
50.6x
EV/EBITDA
14.4x
P/B
1.4x
Debt/Equity
0.9x
ROE
8.3%
P/FCF
19.4x
RSI (14)
—
ATR (14)
—
Beta
1.35
50d MA
$76.43
200d MA
$80.57
Avg Volume
185.9K
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.
1300 West Sam Houston Parkway South · Houston, TX 77042 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.55 | 0.46 | -16.4% | 73.65 | -8.5% | -19.9% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.67 | 0.67 | +0.0% | 81.68 | -3.0% | -2.9% | +4.6% | +0.1% | +0.3% | +1.0% | — |
| Nov 5, 2025 | AMC | 0.67 | 0.66 | -1.5% | 88.05 | -6.6% | -11.9% | -4.8% | -0.8% | +1.5% | -2.5% | — |
| Aug 6, 2025 | AMC | 0.71 | 0.81 | +14.1% | 72.69 | +9.4% | +15.2% | +4.7% | -1.1% | +0.9% | +1.2% | — |
| May 7, 2025 | AMC | 0.46 | 0.48 | +4.3% | 70.96 | -2.3% | -0.1% | +4.5% | +4.4% | -0.2% | +0.1% | — |
| Feb 26, 2025 | AMC | 0.69 | 0.65 | -5.8% | 87.72 | -6.4% | -6.0% | -1.7% | -1.7% | -0.3% | +2.3% | — |
| Nov 5, 2024 | AMC | 0.68 | 0.69 | +1.5% | 82.53 | +5.9% | +17.7% | -1.9% | -0.2% | -0.5% | -2.7% | — |
| Aug 13, 2024 | AMC | 0.81 | 0.73 | -9.9% | 90.00 | -7.8% | -9.3% | +1.8% | +1.3% | -0.2% | -2.7% | — |
| May 7, 2024 | AMC | 0.56 | 0.51 | -8.9% | 105.59 | -2.8% | -1.6% | +1.1% | +1.3% | -1.3% | +1.4% | — |
| Feb 28, 2024 | AMC | 0.57 | 0.59 | +3.5% | 99.87 | +2.2% | +6.4% | -1.6% | +1.0% | -1.6% | +1.0% | — |
| Nov 7, 2023 | AMC | 0.62 | 0.62 | +0.0% | 85.25 | -5.0% | -2.9% | -2.7% | +2.2% | -0.1% | +6.0% | — |
| Aug 8, 2023 | AMC | 0.75 | 0.76 | +1.3% | 120.02 | -3.8% | -9.2% | +1.1% | -0.6% | -2.3% | -1.9% | — |
| May 3, 2023 | AMC | 0.52 | 0.59 | +13.5% | 106.38 | +1.1% | +2.0% | +5.2% | +0.2% | -3.6% | +2.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20 | Barrington Research | Maintains | Outperform → Outperform | — | $86.45 | $86.22 | -0.3% | -1.6% | -1.8% | -0.8% | -1.4% | -2.9% |
| Jan 5 | Barrington Research | Maintains | Outperform → Outperform | — | $78.88 | $79.73 | +1.1% | +6.8% | -3.5% | -2.2% | +2.5% | +3.0% |
| Nov 24 | JP Morgan | Maintains | Overweight → Overweight | — | $71.63 | $72.00 | +0.5% | -0.2% | +3.7% | -0.3% | -0.1% | -0.4% |
| Oct 24 | Barrington Research | Maintains | Outperform → Outperform | — | $91.34 | $92.55 | +1.3% | +2.0% | -2.3% | -1.2% | -2.1% | -2.1% |
| Aug 8 | Barrington Research | Maintains | Outperform → Outperform | — | $83.75 | $83.02 | -0.9% | +4.7% | -1.1% | +0.9% | +1.2% | -2.9% |
| Jul 1 | Barrington Research | Maintains | Outperform → Outperform | — | $78.20 | $77.90 | -0.4% | +3.1% | +0.1% | +1.8% | -3.4% | -3.3% |
| Apr 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $66.31 | $67.39 | +1.6% | +2.4% | +1.3% | +1.4% | +1.2% | +1.0% |
| Mar 19 | JP Morgan | Maintains | Overweight → Overweight | — | $76.17 | $76.28 | +0.1% | -0.2% | -1.8% | -2.5% | +1.2% | -0.5% |
| Feb 28 | Barrington Research | Maintains | Outperform → Outperform | — | $82.42 | $82.63 | +0.3% | -1.7% | -1.7% | -0.3% | +2.3% | +2.1% |
| Dec 16 | BofA Securities | Upgrade | Neutral → Buy | — | $93.46 | $96.21 | +2.9% | +2.2% | -0.6% | -2.7% | -1.1% | -0.1% |
| Dec 3 | JP Morgan | Maintains | Overweight → Overweight | — | $99.37 | $100.65 | +1.3% | -0.4% | +0.9% | -2.3% | -1.6% | +0.4% |
| Nov 21 | Barrington Research | Maintains | Outperform → Outperform | — | $94.06 | $94.22 | +0.2% | +3.1% | +0.9% | +0.2% | +0.6% | -1.5% |
| Nov 7 | Barrington Research | Maintains | Outperform → Outperform | — | $97.10 | $96.66 | -0.5% | -1.9% | -0.2% | -0.5% | -2.7% | -0.2% |
| Oct 9 | Barrington Research | Maintains | Outperform → Outperform | — | $77.48 | $76.89 | -0.8% | +0.9% | -0.9% | +3.6% | +2.0% | +0.5% |
| Oct 7 | BofA Securities | Downgrade | Buy → Neutral | — | $81.05 | $78.73 | -2.9% | -3.2% | -1.3% | +0.9% | -0.9% | +3.6% |
| Sep 20 | Barrington Research | Maintains | Outperform → Outperform | — | $85.02 | $85.41 | +0.5% | -2.0% | -0.3% | +1.0% | +0.5% | -0.1% |
| Aug 15 | Barrington Research | Maintains | Outperform → Outperform | — | $81.64 | $83.23 | +1.9% | +1.8% | +1.3% | -0.2% | -2.7% | +1.6% |
| May 9 | Barrington Research | Maintains | Outperform → Outperform | — | $103.92 | $103.79 | -0.1% | +1.1% | +1.3% | -1.3% | +1.4% | +1.5% |
| Mar 13 | JP Morgan | Maintains | Overweight → Overweight | — | $106.26 | $107.00 | +0.7% | +1.3% | -1.0% | +0.1% | +0.3% | +2.0% |
| Mar 1 | Barrington Research | Maintains | Outperform → Outperform | — | $106.27 | $106.58 | +0.3% | -1.6% | +1.0% | -1.6% | +1.0% | +0.3% |
| Jan 3 | Barrington Research | Maintains | Outperform → Outperform | — | $93.47 | $93.47 | +0.0% | -1.2% | +1.1% | -0.6% | +1.6% | -0.7% |
| Nov 17 | JP Morgan | Maintains | Overweight → Overweight | — | $85.37 | $85.73 | +0.4% | -0.8% | +1.6% | -1.1% | +2.6% | +0.8% |
| Nov 9 | Barrington Research | Maintains | Outperform → Outperform | — | $82.76 | $82.16 | -0.7% | -2.7% | +2.2% | -0.1% | +6.0% | -0.2% |
| Sep 19 | CJS Securities | Upgrade | Market Perform → Market Outperform | — | $94.86 | $94.80 | -0.1% | +0.8% | +0.9% | -1.8% | +0.6% | +1.7% |
| Aug 14 | Barrington Research | Maintains | Outperform → Outperform | — | $109.60 | $109.49 | -0.1% | -2.3% | -1.9% | -3.6% | +0.4% | +0.5% |
| May 5 | Barrington Research | Maintains | Outperform → Outperform | — | $108.49 | $110.00 | +1.4% | +5.2% | +0.2% | -3.6% | +2.8% | -1.6% |
| Feb 24 | Barrington Research | Maintains | Outperform → Outperform | — | $99.94 | $99.28 | -0.7% | -1.2% | +1.0% | +1.6% | +0.6% | -0.8% |
| Dec 14 | CJS Securities | Upgrade | Market Perform → Market Outperform | — | $93.90 | $93.56 | -0.4% | +1.4% | +0.6% | -1.7% | +3.3% | -3.1% |
| May 7 | Barrington Research | Upgrade | Market Perform → Outperform | — | $116.77 | $119.51 | +2.3% | +2.0% | -0.8% | -0.6% | -3.2% | +2.5% |
| May 3 | Jefferies | Upgrade | Hold → Buy | — | $112.45 | $115.99 | +3.1% | +4.6% | -1.3% | -3.1% | +3.8% | +2.0% |
| Feb 26 | Barrington Research | Downgrade | Outperform → Market Perform | — | $116.31 | $116.03 | -0.2% | +0.8% | -0.8% | -2.4% | -2.4% | -0.1% |
| Mar 27 | Sidoti & Co. | Maintains | Buy → Buy | — | $70.00 | $67.00 | -4.3% | -7.8% | +7.4% | -0.4% | -14.5% | +1.1% |
| Nov 8 | Barrington Research | Upgrade | Market Perform → Outperform | — | $119.18 | $119.20 | +0.0% | -1.4% | -0.4% | -0.0% | -3.0% | +1.6% |
| Nov 2 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $115.56 | $115.50 | -0.1% | -2.2% | +1.1% | +0.2% | +1.7% | -0.1% |
| May 4 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $90.00 | $87.90 | -2.3% | +0.7% | +1.0% | -0.1% | +0.6% | +0.0% |
| Nov 3 | Barrington Research | Downgrade | Outperform → Market Perform | — | $72.05 | $70.95 | -1.5% | -8.0% | +0.2% | -0.5% | +1.4% | +2.0% |
| Mar 17 | Barrington Research | Downgrade | Outperform → Market Perform | — | $69.90 | $69.40 | -0.7% | -2.5% | -0.4% | -4.6% | -0.9% | -1.8% |
| Nov 4 | Barrington Research | Upgrade | Market Perform → Outperform | — | $53.20 | $53.60 | +0.8% | +4.3% | +1.2% | +0.5% | +0.4% | +1.9% |
| Aug 5 | Jefferies | Maintains | Hold → Hold | — | $60.88 | $60.20 | -1.1% | +0.5% | -1.4% | +0.7% | -0.5% | +1.3% |
| May 6 | Barrington Research | Upgrade | Market Perform → Outperform | — | $51.83 | $51.91 | +0.2% | +9.0% | +3.3% | -1.0% | -0.3% | -1.1% |
| Mar 1 | Jefferies | Downgrade | Buy → Hold | — | $50.69 | $50.47 | -0.4% | -2.6% | +2.1% | +6.7% | -5.2% | +0.6% |
| May 6 | Barrington Research | Upgrade | Market Perform → Outperform | — | $44.99 | $43.55 | -3.2% | +0.1% | +2.3% | +5.5% | +1.1% | -1.4% |
| Oct 28 | Jefferies | Maintains | Buy → Buy | — | $39.54 | $39.45 | -0.2% | +4.6% | +1.9% | +1.9% | +0.4% | +0.3% |
| Dec 17 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $34.18 | $33.84 | -1.0% | -0.3% | +1.4% | -0.6% | +1.3% | +0.4% |
| Aug 12 | Noble Capital Markets | Downgrade | Buy → Hold | — | $31.24 | $30.74 | -1.6% | -0.9% | -0.0% | -1.0% | -4.6% | -0.2% |
| Aug 12 | Noble Financial | Downgrade | Buy → Hold | — | $31.24 | $30.74 | -1.6% | -0.9% | -0.0% | -1.0% | -4.6% | -0.2% |
| Mar 8 | Noble Capital Markets | Upgrade | Hold → Buy | — | $22.89 | $23.61 | +3.1% | +2.5% | -0.7% | +0.7% | +0.6% | +1.0% |
| Mar 8 | Noble Financial | Upgrade | Hold → Buy | — | $22.89 | $23.61 | +3.1% | +2.5% | -0.7% | +0.7% | +0.6% | +1.0% |
| Jan 10 | Noble Capital Markets | Downgrade | Buy → Hold | — | $25.38 | $25.18 | -0.8% | -3.4% | +2.0% | -0.5% | +0.9% | +1.2% |
| Jan 10 | Noble Financial | Downgrade | Buy → Hold | — | $25.38 | $25.18 | -0.8% | -3.4% | +2.0% | -0.5% | +0.9% | +1.2% |
No insider trades available.
— 8-K filing (BAC, USPH)
Apr 15
— 8-K filing (BAC, USPH)
Apr 15
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
Bank of America secured $125 million in financing, potentially strengthening liquidity and reducing borrowing costs, which could improve profitability and support shareholder returns.
Apr 15
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
This dividend equivalent structure on restricted stock units protects equity compensation value during vesting periods, but investors should monitor whether excessive RSU grants dilute shareholder ownership and future earnings per share.
Mar 13
8-K · 7.01
! Medium
US Physical Therapy Inc -- 8-K 7.01: Regulation FD Disclosure
US Physical Therapy updated its investor presentation to provide stakeholders with current information about its outpatient clinic operations and industrial injury prevention services business.
Mar 9
8-K · 7.01
! Medium
US Physical Therapy Inc -- 8-K 7.01: Regulation FD Disclosure
US Physical Therapy disclosed 2025 fourth-quarter and full-year financial results via conference call, providing investors with management commentary on operational performance and business outlook.
Mar 3
8-K · 5.02
!!! Very High
US Physical Therapy Inc -- 8-K 5.02: Executive Change
US Physical Therapy Inc (USPH) lost director Carey Hendrickson through resignation, reducing board oversight depth without specified succession details.
Feb 26
8-K · 8.01
!! High
US Physical Therapy Inc -- 8-K 8.01: Material Event / Announcement
US Physical Therapy's Metro Physical Therapy subsidiary established a 10-year strategic alliance with NYU Langone Health to provide physical therapy services across Long Island and the New York metropolitan area, expanding its market reach.
Feb 4
Data updated apr 27, 2026 7:09am
· Source: massive.com